2024
On June 20, as reported by the Journal Citation Reports (JCR) by Clarivate Analytics, the Journal of Cancer Metastasis and Treatment (JCMT) achieved an updated Impact Factor of 1.4, ranking in Q4 within the field of Oncology.
In June, Scopus released the 2023 CiteScore for Journal of Cancer Metastasis and Treatment (JCMT) , which remains at 3.2, placing the journal in Q3 for Oncology.
2023
In December, six members of the Journal of Cancer Metastasis and Treatment (JCMT) Editorial Board were honored by Clarivate as “2023 Highly Cited Researchers.”
In September, the Journal of Cancer Metastasis and Treatment (JCMT) was officially indexed in Embase.
In June, Clarivate Analytics announced in the Journal Citation Reports (JCR) that the Journal of Cancer Metastasis and Treatment (JCMT) achieved its first impact factor of 1.9 in the field of Oncology.
2022
In December, Journal of Cancer Metastasis and Treatment (JCMT) was indexed in ESCI.
2021
In May, Journal of Cancer Metastasis and Treatment (JCMT) was indexed in Scopus.
2020
In December, the estimated impact factor was 2.01. The total citations of papers published in 2018 and 2019 were 243 times, and the total number of reviews and original articles published was 121. Click the link for details of the citations of JCMT: https://oaepublishstorage.blob.core.windows.net/jcmtuploadedfiles/Citations of JCMT as of Dec. 31 2020.xlsx.
In August, the reorganization of the JCMT Editorial Board was completed.
2019
In March, JCMT became a member of the Committee on Publication Ethics (COPE).
2017
In April, JCMT was promoted at the 108th American Association for Cancer Research (AACR) Annual Meeting.
2016
In Apirl, the first Editorial Board meeting was held in New Orleans, USA.
2015
In April, JCMT was founded with Professor Lucio Miele as the Editor-in-Chief.
